AbbVie, an American publicly traded biopharmaceutical company founded in 2013, is conducting this trial since October 2016 through 2022, wherein participants will receive an injection containing either one of three doses of ABBV-8E12 or a placebo.
Researchers will study the effects of ABBV-8E12, an anti-tau antibody, on abnormal tau accumulation, a hallmark of Alzheimer’s disease. Researchers will also compare changes in participants’ dementia symptoms, cognitive function, and activities of daily living and will also track any safety issues.
Check out the inclusion and exclusion criteria on this link: https://www.nia.nih.gov/alzheimers/clinical-trials/abbv-8e12-early-alzheimers-disease
Leave a Reply